Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):951–955. doi: 10.1038/bjc.1996.463

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

W H Kruit 1, C J Punt 1, S H Goey 1, P H de Mulder 1, J W Gratama 1, A M Eggermont 1, R L Bolhuis 1, G Stoter 1
PMCID: PMC2074736  PMID: 8826864

Abstract

Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of 41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity (28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%).

Full text

PDF
951

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., Sparano J., Fisher R. I., Weiss G. R., Margolin K. A., Fink K. I., Rubinstein L., Louie A., Mier J. W., Gucalp R. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993 Apr;11(4):661–670. doi: 10.1200/JCO.1993.11.4.661. [DOI] [PubMed] [Google Scholar]
  2. Bar M. H., Sznol M., Atkins M. B., Ciobanu N., Micetich K. C., Boldt D. H., Margolin K. A., Aronson F. R., Rayner A. A., Hawkins M. J. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol. 1990 Jul;8(7):1138–1147. doi: 10.1200/JCO.1990.8.7.1138. [DOI] [PubMed] [Google Scholar]
  3. Creagan E. T., Schaid D. J., Ahmann D. L., Frytak S. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations. J Invest Dermatol. 1990 Dec;95(6 Suppl):188S–192S. doi: 10.1111/1523-1747.ep12875512. [DOI] [PubMed] [Google Scholar]
  4. Denicoff K. D., Rubinow D. R., Papa M. Z., Simpson C., Seipp C. A., Lotze M. T., Chang A. E., Rosenstein D., Rosenberg S. A. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987 Sep;107(3):293–300. doi: 10.7326/0003-4819-107-2-293. [DOI] [PubMed] [Google Scholar]
  5. Dillman R. O., Church C., Oldham R. K., West W. H., Schwartzberg L., Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer. 1993 Apr 1;71(7):2358–2370. doi: 10.1002/1097-0142(19930401)71:7<2358::aid-cncr2820710730>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  6. Dutcher J. P., Gaynor E. R., Boldt D. H., Doroshow J. H., Bar M. H., Sznol M., Mier J., Sparano J., Fisher R. I., Weiss G. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol. 1991 Apr;9(4):641–648. doi: 10.1200/JCO.1991.9.4.641. [DOI] [PubMed] [Google Scholar]
  7. Fosså S. D., Aune H., Baggerud E., Granerud T., Heilo A., Theodorsen L. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma. Eur J Cancer. 1993;29A(9):1313–1315. doi: 10.1016/0959-8049(93)90080-y. [DOI] [PubMed] [Google Scholar]
  8. Gratama J. W., Schmitz P. I., Goey S. H., Lamers C. H., Stoter G., Bolhuis R. L. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes). Int J Cancer. 1996 Jan 17;65(2):152–160. doi: 10.1002/(SICI)1097-0215(19960117)65:2<152::AID-IJC5>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  9. Keilholz U., Scheibenbogen C., Tilgen W., Bergmann L., Weidmann E., Seither E., Richter M., Brado B., Mitrou P. S., Hunstein W. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer. 1993 Jul 15;72(2):607–614. doi: 10.1002/1097-0142(19930715)72:2<607::aid-cncr2820720245>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  10. Khayat D., Borel C., Tourani J. M., Benhammouda A., Antoine E., Rixe O., Vuillemin E., Bazex P. A., Thill L., Franks R. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993 Nov;11(11):2173–2180. doi: 10.1200/JCO.1993.11.11.2173. [DOI] [PubMed] [Google Scholar]
  11. Kruit W. H., Goey S. H., Calabresi F., Lindemann A., Stahel R. A., Poliwoda H., Osterwalder B., Stoter G. Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer. 1995 Jun;71(6):1319–1321. doi: 10.1038/bjc.1995.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Legha S. S., Buzaid A. C. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol. 1993 Dec;20(6 Suppl 9):27–32. [PubMed] [Google Scholar]
  13. Marincola F. M., White D. E., Wise A. P., Rosenberg S. A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol. 1995 May;13(5):1110–1122. doi: 10.1200/JCO.1995.13.5.1110. [DOI] [PubMed] [Google Scholar]
  14. Parkinson D. R., Abrams J. S., Wiernik P. H., Rayner A. A., Margolin K. A., Van Echo D. A., Sznol M., Dutcher J. P., Aronson F. R., Doroshow J. H. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990 Oct;8(10):1650–1656. doi: 10.1200/JCO.1990.8.10.1650. [DOI] [PubMed] [Google Scholar]
  15. Richards J. M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992 Aug;10(8):1338–1343. doi: 10.1200/JCO.1992.10.8.1338. [DOI] [PubMed] [Google Scholar]
  16. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  18. Rosenberg S. A., Lotze M. T., Yang J. C., Topalian S. L., Chang A. E., Schwartzentruber D. J., Aebersold P., Leitman S., Linehan W. M., Seipp C. A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993 Apr 21;85(8):622–632. doi: 10.1093/jnci/85.8.622. [DOI] [PubMed] [Google Scholar]
  19. Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994 Mar 23;271(12):907–913. [PubMed] [Google Scholar]
  20. Sparano J. A., Fisher R. I., Sunderland M., Margolin K., Ernest M. L., Sznol M., Atkins M. B., Dutcher J. P., Micetich K. C., Weiss G. R. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993 Oct;11(10):1969–1977. doi: 10.1200/JCO.1993.11.10.1969. [DOI] [PubMed] [Google Scholar]
  21. Sznol M., Clark J. W., Smith J. W., 2nd, Steis R. G., Urba W. J., Rubinstein L. V., VanderMolen L. A., Janik J., Sharfman W. H., Fenton R. G. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst. 1992 Jun 17;84(12):929–937. doi: 10.1093/jnci/84.12.929. [DOI] [PubMed] [Google Scholar]
  22. Whitehead R. P., Kopecky K. J., Samson M. K., Costanzi J. J., Natale R. B., Feun L. G., Hersh E. M., Rinehart J. J. Phase II study of intravenous bolus recombinant interleukin-2 in advanced malignant melanoma: Southwest Oncology Group study. J Natl Cancer Inst. 1991 Sep 4;83(17):1250–1252. doi: 10.1093/jnci/83.17.1250. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES